BioCentury
BioCentury
ARTICLE | Product Development

The TAC universe grows beyond PROTACs

Inducing autophagy is becoming a popular strategy as targeting chimeras extend beyond protein degradation

By Danielle Golovin, Staff Writer
August 20, 2021 5:13 PM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Arvinas Inc.

Kymera Therapeutics Inc.

Vividion Therapeutics Inc.

Bayer AG

PAQ Therapeutics Inc.

Autotac Bio. Inc.

Frontier Medicines Corp.

BCIQ Target Profiles

Cereblon (CRBN)

Microtubule-associated protein 1 light chain 3 beta (MAP1LC3B) (LC3B)

Sequestosome 1 (SQSTM1) (p62)

Huntingtin (HTT)

Macrophage migration inhibitory factor (MIF)

BCIQ Company Profiles

Arvinas Inc.

Kymera Therapeutics Inc.

Vividion Therapeutics Inc.

Bayer AG

PAQ Therapeutics Inc.

Autotac Bio. Inc.

Frontier Medicines Corp.

BCIQ Target Profiles

Cereblon (CRBN)

Microtubule-associated protein 1 light chain 3 beta (MAP1LC3B) (LC3B)

Sequestosome 1 (SQSTM1) (p62)

Huntingtin (HTT)

Macrophage migration inhibitory factor (MIF)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS